BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 15, 2025
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Biggest gainers and losers for the week of Nov. 22-24, 2021

Nov. 24, 2021
The top 10 biopharma stock gainers and losers for the week.
Read More
Health professional pointing stethoscope at Clinical Trial words, icons

Clinical news slows, but still up 7% over last year

Nov. 19, 2021
By Karen Carey
Efforts to find new treatments for cancer and infectious diseases account for nearly half of the phase I, II and III clinical data recorded in 2021.
Read More
British flag

COVID-19 hits UK’s research charities where it hurts: funding

Nov. 19, 2021
By Nuala Moran
LONDON – Medical research charities that form an integral part of the U.K. health research system are still reeling from the impact of COVID-19 and now expect it will be three years before funding returns to pre-pandemic levels.
Read More

Strong $47B financing year trails 2020 by 16%

Nov. 19, 2021
By Karen Carey
As the COVID-19 pandemic emerged in early 2020 and med-tech companies stepped up with numerous diagnostic and telehealth solutions, the availability of funding sources began to soar. The med-tech industry has raised a total of $46.9 billion so far in 2021 through 636 financings.
Read More

Med-tech gainers and losers for Nov. 15-19, 2021

Nov. 19, 2021
The top 10 med-tech stock gainers and losers for the week.
Read More
Stock chart, upward arrow

Biggest gainers and losers for the week of Nov. 15-19, 2021

Nov. 19, 2021
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-Nov. 18, 2021

Nov. 19, 2021
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2021 vs. 2020 vs. 2019

Nov. 19, 2021
Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019.
Read More
Drug research

Moderna tumbles on lower revenue: ‘COVID trade couldn’t go on forever’

Nov. 17, 2021
By Karen Carey
After Moderna Inc. lowered its revenue expectations earlier this month, the company’s swollen stock price plunged over the next two weeks by more than 32%, signifying that BioWorld’s Drug Developers Index can no longer rely solely on one company to keep industry stocks in positive territory.
Read More
Cancer cell and DNA

Cancer index remains low on safety issues and BLA withdrawal

Nov. 16, 2021
By Karen Carey
Continuing its downward trend, BioWorld’s Cancer Index (BCI) has fallen by 19.16% this year, a stark contrast with the broader Nasdaq Biopharmaceutical Index and the Dow Jones Industrial Average, both of which are tracking up by 4.49% and 19.03%, respectively. Two-thirds of the 21 stocks that make up BCI are showing losses so far this year, and everything from disappointing sales, strong competition, clinical holds and safety issues are to blame.
Read More
Previous 1 2 … 151 152 153 154 155 156 157 158 159 … 263 264 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing